Telix Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging proprietary radiochemistry technologies, Telix aims to deliver precision oncology solutions by linking radioisotopes to targeting molecules that seek out tumor cells. Its pipeline spans both diagnostic products, which assist physicians in accurately visualizing disease, and therapeutic products, which deliver targeted radiation to cancerous tissues.
The company’s lead diagnostic candidate, TLX250-CDx (marketed as Illuccix™ in the U.S.), is an 18F-labeled prostate-specific membrane antigen (PSMA) PET imaging agent designed to detect and stage prostate cancer. Following U.S. Food and Drug Administration approval in 2023, Illuccix became one of the first 18F-based PSMA diagnostics available to clinicians, with commercial launches underway in North America and Europe. On the therapeutic front, Telix is advancing a portfolio of radioligand therapies (RLTs) using lutetium-177 and zirconium-89 isotopes, each tailored to target specific tumor antigens in cancers such as renal cell carcinoma and glioblastoma.
Founded in 2015 as an offshoot from established radiopharmaceutical expertise in Australia, Telix has quickly expanded its global footprint. Headquartered in Melbourne, the company maintains operations and strategic partnerships across the United States, Europe and Asia, enabling local manufacturing, regulatory submissions and commercialization of its products. Through alliances with academic centers and contract manufacturing organizations, Telix has built a scalable infrastructure for late-stage clinical trials and commercial supply of its radiopharmaceuticals.
Under the leadership of Chief Executive Officer Dr. Christian Behrenbruch, Telix continues to advance a robust clinical development plan, including multiple pivotal studies in oncology indications with high unmet medical need. The company’s board and scientific advisory team comprise experts in nuclear medicine, oncology and pharmaceutical development, supporting Telix’s mission to transform cancer diagnosis and therapy through innovative radiopharmaceutical science.
AI Generated. May Contain Errors.
